Literature DB >> 12819115

Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM(197) differs depending on the serotype of the attached polysaccharide.

Ethan G Leonard1, David H Canaday, Clifford V Harding, John R Schreiber.   

Abstract

The pneumococcal (Pn) conjugate vaccine includes seven different polysaccharides (PS) conjugated to CRM(197). Utilizing antigen-processing cells and a CRM(197)-specific mouse T-cell hybridoma, we found that the serotype of conjugated PnPS dramatically affected antigen processing of CRM(197). Unconjugated CRM(197) and serotype conjugates 14 and 18C were processed more efficiently.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12819115      PMCID： PMC161992          DOI： 10.1128/IAI.71.7.4186-4189.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  23 in total

1.  Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein.

Authors:  Kulwant K Kamboj; H Lester Kirchner; Rhonda Kimmel; Neil S Greenspan; John R Schreiber
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

2.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

3.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

4.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

5.  Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages.

Authors:  E H Noss; C V Harding; W H Boom
Journal:  Cell Immunol       Date:  2000-04-10       Impact factor: 4.868

6.  Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b.

Authors:  D H Smith; G Peter; D L Ingram; A L Harding; P Anderson
Journal:  Pediatrics       Date:  1973-11       Impact factor: 7.124

7.  Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins.

Authors:  T Uchida; A M Pappenheimer; A A Harper
Journal:  Science       Date:  1972-02-25       Impact factor: 47.728

8.  Pneumococcal polysaccharide immunization in infants and children.

Authors:  M J Cowan; A J Ammann; D W Wara; V M Howie; L Schultz; N Doyle; M Kaplan
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

9.  Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model.

Authors:  F Mawas; I M Feavers; M J Corbel
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

10.  Antibody response to pneumococcal vaccination in children younger than five years of age.

Authors:  R M Douglas; J C Paton; S J Duncan; D J Hansman
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226
View more
  6 in total

1.  The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites.

Authors:  Christoph Schneider; David F Smith; Richard D Cummings; Kayluz Frias Boligan; Robert G Hamilton; Bruce S Bochner; Sylvia Miescher; Hans-Uwe Simon; Anastas Pashov; Tchavdar Vassilev; Stephan von Gunten
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

2.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

3.  Evaluation of Protective Efficacy of Selected Immunodominant B-Cell Epitopes within Virulent Surface Proteins of Streptococcus pneumoniae.

Authors:  Theodora Papastamatiou; John G Routsias; Olga Koutsoni; Eleni Dotsika; Athanassios Tsakris; Vana Spoulou
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

4.  Macrophages pulsed with Streptococcus pneumoniae elicit a T cell-dependent antibody response upon transfer into naive mice.

Authors:  Sam Vasilevsky; Jesus Colino; Roman Puliaev; David H Canaday; Clifford M Snapper
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

5.  A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.

Authors:  Fikri Y Avci; Xiangming Li; Moriya Tsuji; Dennis L Kasper
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

6.  Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: a randomized controlled trial in Papua New Guinea.

Authors:  Anita H J van den Biggelaar; Peter C Richmond; William S Pomat; Suparat Phuanukoonnon; Marie A Nadal-Sims; Catherine J Devitt; Peter M Siba; Deborah Lehmann; Patrick G Holt
Journal:  Vaccine       Date:  2009-01-14       Impact factor: 3.641
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.